Skip to main content
Log in

Reversal of target-specific oral anticoagulants

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The target-specific oral anticoagulants represent the first new oral anti-thrombotic therapy in over 50 years and have the potential to make therapy easier and hence more accessible to many patients. Like any new therapy, the potential benefits must be weighed against the potential challenges and one of the most concerning aspects of the new target-specific oral anticoagulants is the lack of a proven method to reverse their effect. Unlike the vitamin K antagonist, i.e. warfarin, there is no specific antidote for these medications. This paper will review the limited data on the use of non-specific therapies to reverse anticoagulation for the new agents. We hope to prepare clinicians who are faced with a patient who has serious bleeding or needs emergent surgery while taking dabigatran, rivaroxaban or apixaban.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 106(3):429–438. doi:10.1160/TH11-01-0052

    Article  PubMed  CAS  Google Scholar 

  2. Levi M, Levy JH, Andersen HF, Truloff D (2010) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363(19):1791–1800. doi:10.1056/NEJMoa1006221

    Article  PubMed  CAS  Google Scholar 

  3. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e152S–e184S. doi:10.1378/chest.11-2295

    Article  PubMed  CAS  Google Scholar 

  4. van Ryn J, Litzenburger T, Waterman A, Canada K, Hauel N, Sarko C, Kroe-Barrett R, Singh S, Park J (2011) Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 57(14):E1130

    Article  Google Scholar 

  5. Lu G, Luan P, Hollenbach S, Abe K, DeGuzman F, Siu G, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2009) Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 7(Suppl 2):107

    Google Scholar 

  6. Crowther MA, Warkentin TE (2009) Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 7(Suppl 1):107–110. doi:10.1111/j.1538-7836.2009.03429.x

    Article  PubMed  CAS  Google Scholar 

  7. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579. doi:10.1161/CIRCULATIONAHA.111.029017

    Article  PubMed  CAS  Google Scholar 

  8. Perzborn E, Tinel H (2009) Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. J Thromb Haemost 7(suppl 2):379

    Google Scholar 

  9. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME (2010) Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 116(5):693–701. doi:10.1182/blood-2009-11-253492

    Article  PubMed  CAS  Google Scholar 

  10. van Ryn J, Sieger P, Kink-Eiband M, Gansser D, Clemens A (2009) Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. Blood 114(22):440

    Google Scholar 

  11. Stangier J, Rathgen K, Stahle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259–268. doi:10.2165/11318170-000000000-00000

    Article  PubMed  CAS  Google Scholar 

  12. Wagner F, Peters H, Formella S, Wiegert E, Moschetti V, Khadzhynov D, Clemens A (2011) Effective elimination of dabigatran with haemodialysis: a phase I single centre study in patients with end-stage renal disease. Circulation 124(21 Suppl):A10956

    Google Scholar 

  13. Van Ryn J, Neubauer M, Flieg R, Krause B, Storr M, Hauel N, Priepke H, Clemens A (2010) Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Haematologica 95:293

    Article  Google Scholar 

  14. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42(12):3594–3599. doi:10.1161/STROKEAHA.111.624650

    Article  PubMed  Google Scholar 

  15. van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W (2008) Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor viia or activated prothrombin complex concentrate. Haematologica 93:148

    Google Scholar 

  16. van Ryn J, Schurer J, Kink-Eiband M, Clemens A (2011) The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood 118(21):1004

    Google Scholar 

  17. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield W (2012) Prothrombin complex concentrates reduce blood loss in mice rendered coagulopathic by warfarin but not dabigatran etexilate. Transfusion 52:56A–57A

    Article  Google Scholar 

  18. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217–224. doi:10.1160/TH12-03-0179

    Article  PubMed  CAS  Google Scholar 

  19. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J (2012) Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 10(9):1841–1848. doi:10.1111/j.1538-7836.2012.04859.x

    Article  PubMed  CAS  Google Scholar 

  20. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S (2012) The use of FEIBA(®) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol. doi:10.1111/ijlh.12005

    Google Scholar 

  21. Johnson & Johnson Pharmaceutical Research & Development LLC (2009) Advisory Committee briefing book: rivaroxaban for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in Patients undergoing hip or knee replacement surgery. Johnson & Johnson Pharmaceutical Research & Development, L.L.C, San Diego

  22. PDR.net (2012) http://www.pdr.net/drugpages/productlabeling.aspx?mpcode=40229000. Accessed 20 Nov 2012

  23. Tinel H, Huetter J, Perzborn E (2006) Partial reversal of the anticoagulant effect of high-dose rivaroxaban—an oral, direct factor Xa inhibitor—by recombinant factor VIIa in rats. Blood 108(11):274A

    Google Scholar 

  24. Gruber A, Marzec UM, Buetehorn U, Hanson S, Perzborn E (2008) Potential of activated prothrombin complex concentrate and activated factor vii to reverse the anticoagulant effects of rivaroxaban in primates. Blood 112(11):1307

    Google Scholar 

  25. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116(1):94–102. doi:10.1097/ALN.0b013e318238c036

    Article  PubMed  CAS  Google Scholar 

  26. European Medicines Agency SMH Assessment report for Eliquis (2011) European Medicines Agency, Science Medicines Health, London

  27. Escolar GA-RE, Reverter JC, Villalta J, Sanz V, Molina P, Diaz-Ricart M, Galan AM (2012) Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Circulation 126(4):2

    Google Scholar 

  28. Miyares MA, Davis K (2012) Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 69(17):1473–1484. doi:10.2146/ajhp110725

    Article  PubMed  CAS  Google Scholar 

  29. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87(Suppl 1):S141–S145

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Scott Kaatz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaatz, S., Crowther, M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis 36, 195–202 (2013). https://doi.org/10.1007/s11239-013-0923-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-013-0923-y

Keywords

Navigation